Financial Data and Key Metrics Changes - Consolidated revenues for Q3 2022 decreased by 6% to $2.4 million compared to $2.6 million in Q3 2021, primarily driven by declines in TRxADE Prime and Community Specialty Pharmacy [19] - Gross profit increased to $1.4 million or 58% of revenue, up from $1.3 million and 50% of revenue in Q3 2021, attributed to increased revenues from the TRxADE platform and improved gross margins of TRxADE Prime [23] - Net loss for Q3 2022 was negative $0.5 million or negative $0.06 per share, compared to a net loss of negative $1.3 million or negative $0.16 per share in Q3 2021 [25] Business Line Data and Key Metrics Changes - Revenues generated by the TRxADE platform increased by 6% in Q3 2022 compared to the same quarter in 2021 [19] - TRxADE Prime experienced an 11% decline in revenue for Q3 2022 compared to Q3 2021, but gross margin improved to a positive 3% from a negative 6% [20][21] - The volume of sales processed across the TRxADE platform increased by 18% in Q3 2022 compared to the same quarter in 2021 [16] Market Data and Key Metrics Changes - The company reported over 14,100 registered members on its platform, with approximately 291 new members added in Q3 2022, compared to 195 in Q3 2021 [15] - The Community Specialty Pharmacy's revenue decline was partially attributed to decreased sales in the last week of September due to Hurricane Ian [22] Company Strategy and Development Direction - The company is focusing on strategic partnerships to enhance its core business and diversify revenue streams, including partnerships with insurance brokerage firms and telemedicine services [8][28] - The company aims to digitalize the retail pharmacy experience through optimization of drug procurement and patient engagement [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing challenges posed by COVID-19, increased interest rates, and inflation, but remains optimistic about the company's growth trajectory [4] - The company is working towards operational breakeven and is focused on improving both top-line and bottom-line performance [36] Other Important Information - Cash and cash equivalents were $0.3 million as of September 30, 2022, down from $3.1 million as of December 31, 2021, primarily due to expenditures on salaries, inventory, and legal settlements [26] - The company closed the sale of approximately $1.75 million of common stock, with net cash proceeds of approximately $1.5 million intended for working capital and strategic growth [17] Q&A Session Summary Question: Can you talk about the strategic direction for TRxADE Prime? - Management emphasized a focus on both top-line growth and gross margin improvement, implementing AI to enhance pricing and customer service [31] Question: Any updates on Bonum Health and its rollout? - Management indicated that Bonum Health is still in a nascent phase, seeking strategic buyers or joint ventures to enhance its offering [32] Question: Will the engagement of insurance brokerage firms lead to faster uptake than pharmacy partners? - Management confirmed that the intention is to target uninsured small businesses through these brokerage firms [34] Question: What is the status of the SOSRx joint venture? - Management noted that adoption is slow as manufacturers are accustomed to traditional business methods, similar to the early days of TRxADE [35] Question: Can we expect operational breakeven in the first half of next year? - Management stated that while they cannot predict a timeline, they are working towards positive financial results [36] Question: What was the impact of Hurricane Ian on revenue? - Management confirmed that the last week of Q3 was affected, but patients returned in the subsequent quarter [42][43] Question: Were there any significant one-time impacts in the quarter? - Management mentioned a recovery of $164,000 from a previous bad debt write-off, but no other significant one-time impacts were noted [45]

TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q2 2022 Earnings Conference Call July 25, 2022 5:00 PM ET Company Participants Suren Ajjarapu - Founder, Chairman and CEO Janet Huffman - Chief Financial Officer Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TRxADE HEALTH Second Quarter 2022 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | -- ...

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 (Exact name of registrant as specified in its charter) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _____________to______________ Commission File Number: 001-39199 TRxADE HEALTH, INC. | Delaware | 46-3673928 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRXADE GROUP, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Delaware 46-3673928 (State or Other Jurisdiction of Incorporation or Organization) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _____________to______________ 001-39199 (Commission File Number) TRXADE GROUP, INC. (E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRXADE GROUP, INC. FORM 10-Q (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- | ...